

MERIDIAN BIOSCIENCE INC

Form 10-Q

August 09, 2012

[Table of Contents](#)

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## Form 10-Q

x **QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the Quarterly Period Ended June 30, 2012

OR

.. **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from            to

Commission file number 0-14902

# MERIDIAN BIOSCIENCE, INC.

Incorporated under the laws of Ohio

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 10-Q

31-0888197

(I.R.S. Employer Identification No.)

3471 River Hills Drive

Cincinnati, Ohio 45244

(513) 271-3700

Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer   
Non-accelerated filer  Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Outstanding July 31, 2012
Common Stock, no par value	41,272,339

**Table of Contents****MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES****INDEX TO QUARTERLY REPORT ON FORM 10-Q**

	<b>Page(s)</b>
<b>PART I. FINANCIAL INFORMATION</b>	
Item 1. Financial Statements (Unaudited)	
<u>Condensed Consolidated Statements of Operations Three and Nine Months Ended June 30, 2012 and 2011</u>	1
<u>Condensed Consolidated Statements of Cash Flows Nine Months Ended June 30, 2012 and 2011</u>	2
<u>Condensed Consolidated Balance Sheets June 30, 2012 and September 30, 2011</u>	3-4
<u>Condensed Consolidated Statement of Changes in Shareholders' Equity Nine Months Ended June 30, 2012</u>	5
<u>Notes to Condensed Consolidated Financial Statements</u>	6-10
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	11-19
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	19
Item 4. <u>Controls and Procedures</u>	19
<b>PART II. OTHER INFORMATION</b>	
Item 1A. <u>Risk Factors</u>	19
Item 6. <u>Exhibits</u>	19
<u>Signature</u>	20

*The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as estimates, anticipates, projects, plans, seeks, may, will, expects, intends, believes, should and similar expressions or the negative versions thereof and which also may be identified by their context. Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made. The Company assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following: Meridian's continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian's competition. While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis. Meridian relies on proprietary, patented and licensed technologies, and the Company's ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results. Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution. Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers can change expected results. Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products. The international scope of Meridian's operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict. One of Meridian's main growth strategies is the acquisition of companies and product lines. There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian's operations. There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian's ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives. The Company cannot predict the possible impact of recently-enacted United States healthcare legislation and any similar initiatives in other countries on its results of operations. In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.*

**Table of Contents****PART I. FINANCIAL INFORMATION****Item 1. Financial Statements****MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES****Condensed Consolidated Statements of Operations (Unaudited)****(in thousands, except per share data)**

	Three Months Ended June 30,		Nine Months Ended June 30,	
	2012	2011	2012	2011
NET SALES	\$ 42,141	\$ 40,052	\$ 129,848	\$ 118,374
COST OF SALES	14,498	14,701	47,722	43,564
GROSS PROFIT	27,643	25,351	82,126	74,810
OPERATING EXPENSES				
Research and development	2,660	2,693	7,441	7,328
Selling and marketing	5,843	5,968	17,192	17,041
General and administrative	6,162	6,559	19,236	19,018
Plant consolidation costs	366		1,013	
Sales and marketing leadership reorganization				1,240
Total operating expenses	15,031	15,220	44,882	44,627
OPERATING INCOME	12,612	10,131	37,244	30,183
OTHER INCOME (EXPENSE)				
Interest income	14	26	27	70
Other, net	31	36	304	357
Total other income (expense)	45	62	331	427
EARNINGS BEFORE INCOME TAXES	12,657	10,193	37,575	30,610
INCOME TAX PROVISION	4,063	3,357	12,777	10,489
NET EARNINGS	\$ 8,594	\$ 6,836	\$ 24,798	\$ 20,121
BASIC EARNINGS PER COMMON SHARE	\$ 0.21	\$ 0.17	\$ 0.60	\$ 0.49
DILUTED EARNINGS PER COMMON SHARE	\$ 0.21	\$ 0.17	\$ 0.60	\$ 0.49
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	41,091	40,737	41,075	40,680
EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARES AND UNITS	593	657	530	673
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	41,684	41,394	41,605	41,353
ANTI-DILUTIVE SECURITIES:				
Common share options and restricted shares and units	313	160	309	177
DIVIDENDS DECLARED PER COMMON SHARE	\$ 0.19	\$ 0.19	\$ 0.57	\$ 0.57

Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 10-Q

The accompanying notes are an integral part of these condensed consolidated financial statements.

Page 1

**Table of Contents****MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES****Condensed Consolidated Statements of Cash Flows (Unaudited)**

(dollars in thousands)

	2012	2011
<b>Nine Months Ended June 30,</b>		
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Net earnings	\$ 24,798	\$ 20,121
Non-cash items included in net earnings:		
Depreciation of property, plant and equipment	2,660	2,525
Amortization of intangible assets	1,608	1,796
Amortization of deferred illumigene instrument costs	587	81
Stock-based compensation	1,670	1,981
Deferred income taxes	(1,491)	(1,622)
Loss on disposition and write-down of fixed assets and other assets	203	7
Change in current assets	386	(10,176)
Change in current liabilities	2,474	2,451
Other, net	(1,007)	(546)
Net cash provided by operating activities	31,888	16,618
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchases of property, plant and equipment	(2,985)	(7,666)
Proceeds from sale of assets	400	
Purchases of intangibles and other assets	(1,305)	(12)
Net cash used for investing activities	(3,890)	(7,678)
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Dividends paid	(23,417)	(23,192)
Proceeds and tax benefits from exercises of stock options	399	1,481
Net cash used for financing activities	(23,018)	(21,711)
Effect of Exchange Rate Changes on Cash and Equivalents	(668)	455
Net Increase (Decrease) in Cash and Equivalents	4,312	(12,316)
Cash and Equivalents at Beginning of Period	23,626	37,879
Cash and Equivalents at End of Period	\$ 27,938	\$ 25,563

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Table of Contents****MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES****Condensed Consolidated Balance Sheets****(dollars in thousands)****ASSETS**

	<b>June 30, 2012 (Unaudited)</b>	<b>September 30, 2011</b>
<b>CURRENT ASSETS</b>		
Cash and equivalents	\$ 27,938	\$ 23,626
Accounts receivable, less allowances of \$428 and \$310	24,306	24,844
Inventories	33,120	32,689
Prepaid expenses and other current assets	5,081	6,343
Deferred income taxes	3,393	2,852
<b>Total current assets</b>	<b>93,838</b>	<b>90,354</b>
<b>PROPERTY, PLANT AND EQUIPMENT, at Cost</b>		
Land	1,172	1,184
Buildings and improvements	26,334	23,033
Machinery, equipment and furniture	35,825	32,408
Construction in progress	1,136	3,887
<b>Subtotal</b>	<b>64,467</b>	<b>60,512</b>
Less: accumulated depreciation and amortization	37,928	33,973
<b>Net property, plant and equipment</b>	<b>26,539</b>	<b>26,539</b>
<b>OTHER ASSETS</b>		
Goodwill	22,830	23,124
Other intangible assets, net	10,635	10,947
Restricted cash	1,000	1,000
Deferred illumigene instrument costs, net	3,721	3,304
Other assets	251	225
<b>Total other assets</b>	<b>38,437</b>	<b>38,600</b>
<b>TOTAL ASSETS</b>	<b>\$ 158,814</b>	<b>\$ 155,493</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Table of Contents****MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES****Condensed Consolidated Balance Sheets****(dollars in thousands)****LIABILITIES AND SHAREHOLDERS' EQUITY**

	<b>June 30, 2012 (Unaudited)</b>	<b>September 30, 2011</b>
<b>CURRENT LIABILITIES</b>		
Accounts payable	\$ 6,158	\$ 5,548
Accrued employee compensation costs	4,640	4,235
Other accrued expenses	5,116	4,692
Income taxes payable	1,626	789
Total current liabilities	17,540	15,264
DEFERRED INCOME TAXES	269	1,705
COMMITMENTS AND CONTINGENCIES		
<b>SHAREHOLDERS' EQUITY</b>		
Preferred stock, no par value, 1,000,000 shares authorized, none issued		
Common shares, no par value, 71,000,000 shares authorized, 41,269,062 and 41,237,120 shares issued, respectively		
Additional paid-in capital	102,012	100,010
Retained earnings	39,446	38,065
Accumulated other comprehensive income	(453)	449
Total shareholders' equity	141,005	138,524
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b>\$ 158,814</b>	<b>\$ 155,493</b>

The accompanying notes are an integral part of these condensed consolidated financial statements.



Table of Contents**MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES****Condensed Consolidated Statement of Changes in Shareholders' Equity (Unaudited)**

(dollars and shares in thousands)

	Common Shares Issued	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Comprehensive Income (Loss)	Total Shareholders Equity
<b>Balance at September 30, 2011</b>	41,237	\$ 100,010	\$ 38,065	\$ 449		\$ 138,524
Cash dividends paid			(23,417)			(23,417)
Exercise of stock options	33	332				332
Issuance of restricted shares, net of forfeitures	(3)					
Conversion of restricted stock units	2					
Stock compensation expense		1,670				1,670
Comprehensive income:						
Net earnings			24,798		\$ 24,798	24,798
Other comprehensive income taxes				483	483	483
Foreign currency translation adjustment				(1,385)	(1,385)	(1,385)
Comprehensive income					\$ 23,896	
<b>Balance at June 30, 2012</b>	41,269	\$ 102,012	\$ 39,446	\$ (453)		\$ 141,005

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Table of Contents**

**MERIDIAN BIOSCIENCE, INC. AND SUBSIDIARIES**

**Notes to Condensed Consolidated Financial Statements**

**Dollars in Thousands, Except Per Share Amounts**

**(Unaudited)**

**1. Basis of Presentation**

The interim condensed consolidated financial statements are unaudited and are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, and the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of Management, the interim financial statements include all normal adjustments and disclosures necessary to present fairly the Company's financial position as of June 30, 2012, the results of its operations for the three and nine month periods ended June 30, 2012 and 2011, and its cash flows for the nine month periods ended June 30, 2012 and 2011. These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company's fiscal 2011 Annual Report on Form 10-K. Financial information as of September 30, 2011 has been derived from the Company's audited consolidated financial statements.

The results of operations for interim periods are not necessarily indicative of the results to be expected for the year.

**2. Significant Accounting Policies**

**(a) Revenue Recognition and Accounts Receivable**

Revenue is generally recognized from sales when product is shipped and title has passed to the buyer. Revenue for the U.S. Diagnostics segment is reduced at the date of sale for product price adjustments due certain distributors under local contracts. Management estimates accruals for distributor price adjustments based on local contract terms, sales data provided by distributors, estimates of inventories of our products held by distributors, historical statistics, current trends, and other factors. Changes to the accruals are recorded in the period that they become known. Such accruals were \$3,871 at June 30, 2012 and \$4,176 at September 30, 2011.

Revenue for our Diagnostics segments includes bundled product revenue for our *illumigene*<sup>®</sup> molecular test system. The bundled product includes an instrument, instrument accessories and test kits. If not sold outright, amounts invoiced for the *illumigene*<sup>®</sup> test kits cover the instrument, accessories and test kits. Revenue is recognized based on test kit sales. If not sold outright, costs for the instruments are recognized in cost of sales over the expected instrument utilization period, generally three years.

Life Science revenue for contract services may come from research and development services or manufacturing services, including process development work, or a combination of both. Revenue is recognized based on each of the deliverables in a given arrangement having distinct and separate customer pricing. Pricing is often subject to a competitive bidding process. Contract research and development services may be performed on a time and materials basis or fixed fee basis. For time and materials arrangements, revenue is recognized as services are performed and billed. For fixed fee arrangements, revenue is recognized upon completion and acceptance by the customer. For contract manufacturing services, revenue is generally recognized upon delivery of product and acceptance by the customer. In some cases, customers may request that we store on their behalf, clinical grade biologicals that we produce under contract manufacturing agreements. These cases arise when customers do not have clinical grade storage facilities or do not want to risk contamination during transport. For such cases, revenue may be recognized on a bill-and-hold basis. No such bill-and-hold arrangements existed at June 30, 2012 or September 30, 2011.

**Table of Contents**

Trade accounts receivable are recorded in the accompanying Condensed Consolidated Balance Sheets at invoiced amounts less provisions for distributor price adjustments and doubtful accounts. The allowance for doubtful accounts represents our estimate of probable credit losses and is based on current trends and historical write-off experience. The allowance for doubtful accounts and related metrics, such as days sales outstanding, are reviewed monthly. Accounts with past due balances over 90 days are reviewed individually for collectibility. Customer invoices are charged off against the allowance when we believe it is probable that the invoices will not be paid. Approximately \$5,300 of our accounts receivable at June 30, 2012 is due from Italian hospital customers whose funding ultimately comes from the Italian government. During the fourth quarter of fiscal 2011 and first quarter of fiscal 2012, we experienced a deterioration in the aging of our Italian accounts receivable. While such aging appeared to stabilize during the second and third quarters of fiscal 2012, we continue to monitor such accounts closely.

**(b) Comprehensive Income (Loss)**

Our comprehensive income or loss is comprised of net earnings, foreign currency translation and the related income tax effects.

Assets and liabilities of foreign operations are translated using period-end exchange rates with gains or losses resulting from translation included as a separate component of comprehensive income or loss. Revenues and expenses are translated using exchange rates prevailing during the period. We also recognize foreign currency transaction gains and losses on certain assets and liabilities that are denominated in the Australian dollar, British pound and Euro currencies. These gains and losses are included in other income and expense in the accompanying Condensed Consolidated Statements of Operations.

Comprehensive income for the interim periods was as follows:

	Three Months Ended June 30,		Nine Months Ended June 30,	
	2012	2011	2012	2011
Net earnings	\$ 8,594	\$ 6,836	\$ 24,798	\$ 20,121
Foreign currency translation adjustment	(1,582)	335	(1,385)	1,203
Income taxes	554	(117)	483	(421)
Comprehensive income	\$ 7,566	\$ 7,054	\$ 23,896	\$ 20,903

**(c) Income Taxes**

The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between income for financial reporting and income for tax purposes. We prepare estimates of permanent and temporary differences between income for financial reporting purposes and income for tax purposes. These differences are adjusted to actual upon filing of our tax returns, typically occurring in the third and fourth quarters of the current fiscal year for the preceding fiscal year's estimates.

We account for uncertain tax positions using a benefit recognition model with a two-step approach: (i) a more-likely-than-not recognition criterion; and (ii) a measurement attribute that measures the position as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. If it is not more likely than not that the benefit will be sustained on its technical merits, no benefit is recorded. We recognize accrued interest and penalties related to unrecognized tax benefits as a portion of our income tax provision in the Condensed Consolidated Statements of Operations.

**(d) Stock-based Compensation**

We recognize compensation expense for all share-based awards made to employees, based upon the fair value of the share-based award on the date of the grant. Awards are expensed over their requisite service period.



**Table of Contents****(e) Cash and Cash Equivalents**

Cash and cash equivalents include the following components:

	June 30, 2012		September 30, 2011	
	Cash and Equivalents	Other	Cash and Equivalents	Other
Overnight repurchase agreements	\$ 13,400	\$	\$ 11,784	\$
Cash on hand				
Restricted		1,000		1,000
Unrestricted	14,538		11,842	
<b>Total</b>	<b>\$ 27,938</b>	<b>\$ 1,000</b>	<b>\$ 23,626</b>	<b>\$ 1,000</b>

**(f) Reclassifications**

Certain reclassifications have been made to the prior period financial statements to conform to the current fiscal period presentation. Such reclassifications had no impact on net earnings or shareholders' equity.

**3. Inventories**

Inventories are comprised of the following:

	June 30, 2012	September 30, 2011
Raw materials	\$ 7,147	\$ 7,272
Work-in-process	6,662	7,016
Finished goods - illumigene instruments	2,668	4,179
Finished goods - kits and other	16,643	14,222
<b>Total</b>	<b>\$ 33,120</b>	<b>\$ 32,689</b>

**4. Major Customers and Segment Information**

Meridian was formed in 1976 and functions as a fully-integrated research, development, manufacturing, marketing and sales organization with primary emphasis in the fields of in vitro diagnostics and life science. Our principal businesses are (i) the development, manufacture and distribution of diagnostic test kits primarily for gastrointestinal, viral, respiratory and parasitic infectious diseases; (ii) the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers; and (iii) the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Our reportable segments are U.S. Diagnostics, European Diagnostics and Life Science. Initial segmentation between Diagnostics and Life Science has been determined based upon products and customers, with further segmentation of Diagnostics between U.S. and European being based upon geographic regions served and management responsibility. The U.S. Diagnostics segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the U.S. and countries outside of Australia, Europe, Africa and the Middle East. The European Diagnostics segment consists of the sale and distribution of diagnostic test kits in Australia, Europe, Africa and the Middle East. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides,

## Edgar Filing: MERIDIAN BIOSCIENCE INC - Form 10-Q

competent cells and bioresearch reagents domestically and abroad. The Life Science segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Page 8

**Table of Contents**

During the fourth quarter of fiscal 2011, plans were announced to consolidate the Saco, Maine operations into the Memphis, Tennessee facility. This consolidation of facilities is now complete. During the third quarter and nine months ended June 30, 2012, the Company incurred \$366 and \$1,013, respectively, of costs associated with the facility consolidation, primarily related to employee retention and an additional \$210 write-down of the Maine building facility in the third quarter based on a third-party appraisal. To date, \$2,070 of total costs have been incurred since the announcement of the consolidation in the fourth quarter of fiscal 2011 (\$509 in Cost of Sales and \$1,561 in Operating Expenses). Additional costs related to the consolidation totaling approximately \$60 are expected to be incurred during the remainder of fiscal 2012, with the majority of such costs to be incurred in connection with retention bonus and other employee-related costs.

Two distributor customers accounted for 48% and 47% of the U.S. Diagnostics segment third-party sales during the three months ended June 30, 2012 and 2011, respectively, and 49% and 50% during the nine months ended June 30, 2012 and 2011, respectively. Two diagnostic manufacturing customers accounted for 11% and 15% of the Life Science segment third-party sales during the three months ended June 30, 2012 and 2011, respectively, and 20% and 14% during the nine months ended June 30, 2012 and 2011, respectively.

Segment information for the interim periods is as follows:

	U.S. Diagnostics	European Diagnostics	Life Science	Eliminations (1)	Total
<b>Three Months Ended June 30, 2012</b>					
Net sales -					
Third-party	\$ 26,234	\$ 5,897	\$ 10,010	\$	\$ 42,141
Inter-segment	2,464	5	133	(2,602)	
Operating income (2)	9,442	998	2,118	54	12,612
Goodwill (June 30, 2012)	1,381		21,449		22,830
Other intangible assets, net (June 30, 2012)	2,423		8,212		10,635
Total assets (June 30, 2012)	81,911	16,930	97,150	(37,177)	158,814
<b>Three Months Ended June 30, 2011</b>					
Net sales -					
Third-party	\$ 23,829	\$ 6,612	\$ 9,611	\$	\$ 40,052
Inter-segment	2,875	9	141	(3,025)	
Operating income (3)	8,399	978	797	(43)	10,131
Goodwill (September 30, 2011)	1,381		21,743		23,124
Other intangible assets, net (September 30, 2011)	1,604		9,343		10,947
Total assets (September 30, 2011)	73,850	19,390	92,467	(30,214)	155,493
<b>Nine Months Ended June 30, 2012</b>					
Net sales -					
Third-party	\$ 80,091	\$ 18,326	\$ 31,431	\$	\$ 129,848
Inter-segment	7,428	9	793	(8,230)	
Operating income (2)	29,377	2,398	5,526	(57)	37,244

**Table of Contents****Nine Months Ended June 30, 2011**

Net sales -					
Third-party	\$ 72,007	\$ 18,926	\$ 27,441	\$	\$ 118,374
Inter-segment	7,938	16	459	(8,413)	
Operating income (3)	26,780	1,781	1,499	123	30,183

- (1) Eliminations consist of inter-segment transactions.
- (2) Life Science includes \$366 and \$1,013 of costs related to consolidation of the Maine operations into the Tennessee facility during the three and nine months ended June 30, 2012, respectively.
- (3) U.S. Diagnostics and European Diagnostics include \$365 and \$875, respectively, in the nine months ended June 30, 2011 related to sales and marketing leadership reorganization costs.

Transactions between segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation.

**5. Intangible Assets**

A summary of our acquired intangible assets subject to amortization, as of June 30, 2012 and September 30, 2011 is as follows:

	June 30, 2012		September 30, 2011	
	Gross Carrying Value	Accumulated Amortization	Gross Carrying Value	Accumulated Amortization
Manufacturing technologies, core products and cell lines	\$ 11,625	\$ 9,117	\$ 11,626	\$ 8,545
Trademarks, licenses and patents	4,842	1,667	3,538	1,337
Customer lists and supply agreements	12,219	7,267	12,222	6,557
	\$ 28,686	\$ 18,051	\$ 27,386	\$ 16,439

The actual aggregate amortization expense for these intangible assets was \$545 and \$595 for the three months ended June 30, 2012 and 2011, respectively, and \$1,608 and \$1,796 for the nine months ended June 30, 2012 and 2011, respectively. The estimated aggregate amortization expense for these intangible assets for each of the fiscal years through fiscal 2017 is as follows: remainder of fiscal 2012 \$549, fiscal 2013 \$2,179, fiscal 2014 \$1,743, fiscal 2015 \$1,495, fiscal 2016 \$1,153 and fiscal 2017 \$911.



---

**Table of Contents**

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Refer to *Forward Looking Statements* following the Index in front of this Form 10-Q. In the discussion that follows, all amounts are in thousands (both tables and text), except per share data and percentages.

Following is a discussion and analysis of the financial statements and other statistical data that management believes will enhance the understanding of Meridian's financial condition, changes in financial condition and results of operations. This discussion should be read in conjunction with the financial statements and notes thereto beginning on page 1.

**Results of Operations**

**Three Months Ended June 30, 2012**

Net earnings for the third quarter of fiscal 2012 increased 26% to \$8,594, or \$0.21 per diluted share, from net earnings for the third quarter of fiscal 2011 of \$6,836, or \$0.17 per diluted share. This increase reflects the combined effects of increased sales and stable operating expense levels. The fiscal 2012 third quarter includes \$366 of costs associated with the consolidation of the Saco, Maine operations into the Memphis, Tennessee facility (impact on earnings of \$238, or less than \$0.01 per diluted share). Consolidated sales increased 5% to \$42,141 for the third quarter of fiscal 2012 compared to the same period of the prior year. Sales increases in our *C. difficile* and Foodborne diagnostic focus product families, and our Life Science businesses, contributed to this increase, while sales in our *H. pylori* focus product family were flat compared to the fiscal 2011 third quarter.

Sales for the U.S. Diagnostics segment for the third quarter of fiscal 2012 increased 10% compared to the third quarter of fiscal 2011, reflecting growth across all of our focus product families—6% growth in our *H. pylori* products, 9% growth in our foodborne products, and 25% growth in our *C. difficile* products. Third quarter 2012 sales for our European Diagnostics segment decreased 11% compared to the third quarter of fiscal 2011. On an organic basis, which excludes the effects of currency translation, sales of our European Diagnostics segment were flat compared to the 2011 third quarter. Solid 10% growth in European sales of our *C. difficile* products—resulting in large part from the continued acceptance of our *C. difficile* GDH product, which was introduced internationally during the first quarter of fiscal 2011—served to offset a decrease in *H. pylori* and foodborne product sales within this segment. Primarily reflecting growth in our molecular reagent business, sales of our Life Science segment increased by 4% during the third quarter of fiscal 2012 compared to the third quarter of fiscal 2011.

**Nine Months Ended June 30, 2012**

For the nine month period ended June 30, 2012, net earnings increased 23% to \$24,798, or \$0.60 per diluted share, from net earnings for the comparable fiscal 2011 period of \$20,121, or \$0.49 per diluted share. This increase reflects the combined effects of increased sales and stable operating expense levels. The 2012 year-to-date period includes \$1,013 of costs associated with the consolidation of the Saco, Maine operations into the Memphis, Tennessee facility (impact on earnings of \$659, or \$0.02 per diluted share), while the 2011 period includes \$1,240 of costs related to the reorganization of our European and global sales and marketing leadership during the second quarter of fiscal 2011 (impact on earnings of \$872 or \$0.02 per diluted share). Consolidated sales increased 10% to \$129,848 for the first nine months of fiscal 2012 compared to the same period of the prior fiscal year, reflecting increases in sales across all of our diagnostic focus product families: *C. difficile*, Foodborne and *H. pylori*, and our Life Science businesses.

During the first nine months of fiscal 2012, sales for the U.S. Diagnostics segment increased 11% from the comparable fiscal 2011 period. This increase reflects growth across all of our focus product families—12% growth in our *H. pylori* products, 17% growth in our foodborne products and 30% growth in our *C. difficile* products. Sales of our European Diagnostics segment for the first nine months of fiscal 2012 decreased 3% compared to the first nine months of fiscal 2011. On an organic basis, which excludes the effects of currency translation, sales of our European Diagnostics segment increased 3% during the fiscal 2012 year-to-date period, reflecting growth in our *C. difficile* and *H. pylori* focus product families being partially offset by a decline in sales of our foodborne products. With growth in both its core bulk reagent and molecular reagent businesses, sales of our Life Science segment increased by 15% during the first nine months of fiscal 2012 over the comparable fiscal 2011 period.

**Table of Contents****Non-GAAP Information**

The tables below provide information on net earnings, basic earnings per share and diluted earnings per share, excluding the effect of costs associated with the consolidation of our Saco, Maine operations into our Memphis, Tennessee facility (fiscal 2012) and the reorganizing of our sales and marketing leadership (fiscal 2011), each of which is a non-GAAP financial measure, as well as reconciliations to amounts reported under U.S. Generally Accepted Accounting Principles. We believe that this information is useful to those who read our financial statements and evaluate our operating results because:

1. These measures help to appropriately evaluate and compare the results of operations from period to period by removing the impact of non-routine costs related to consolidating the Maine operations (fiscal 2012) and reorganizing our sales and marketing leadership (fiscal 2011); and
2. These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our Board of Directors, and as a basis for strategic planning and forecasting.

	<b>Three Months Ended June 30,</b>		<b>Nine Months Ended June 30,</b>	
	<b>2012</b>	<b>2011</b>	<b>2012</b>	<b>2011</b>
<b>Net Earnings -</b>				
U.S. GAAP basis	\$ 8,594	\$ 6,836	\$ 24,798	\$ 20,121
Facility consolidation costs (1)	238		659	
Sales & marketing leadership reorganization (2)				872
<b>Adjusted earnings</b>	<b>\$ 8,832</b>	<b>\$ 6,836</b>	<b>\$ 25,457</b>	<b>\$ 20,993</b>
<b>Net Earnings per Basic Common Share -</b>				
U.S. GAAP basis	\$ 0.21	\$ 0.17	\$ 0.60	\$ 0.49
Facility consolidation costs (1)	0.01		0.02	
Sales & marketing leadership reorganization (2)				0.02
<b>Adjusted Basic EPS (3)</b>	<b>\$ 0.21</b>	<b>\$ 0.17</b>	<b>\$ 0.62</b>	<b>\$ 0.52</b>
<b>Net Earnings per Diluted Common Share -</b>				
U.S. GAAP basis	\$ 0.21	\$ 0.17	\$ 0.60	\$ 0.49
Facility consolidation costs (1)	0.01		0.02	
Sales & marketing leadership reorganization (2)				0.02
<b>Adjusted Diluted EPS (4)</b>	<b>\$ 0.21</b>	<b>\$ 0.17</b>	<b>\$ 0.61</b>	<b>\$ 0.51</b>

- (1) These facility consolidation costs are net of income tax effects of \$128 and \$354 for the three and nine month periods, respectively, which were calculated using the effective tax rates of the jurisdictions in which the costs were incurred.
- (2) These leadership reorganization costs are net of the \$368 income tax effect for the nine month period, which was calculated using the effective tax rates of the jurisdictions in which the costs were incurred.
- (3) Net Earnings per Basic Common Share for the three months ended June 30, 2012 and the nine months ended June 30, 2011 do not sum to the total due to rounding.
- (4) Net Earnings per Diluted Common Share for the three and nine months ended June 30, 2012 do not sum to the total due to rounding.



## Table of Contents

### Revenue Overview

Our Diagnostics segments provided the largest share of our consolidated revenues, 76% for the third quarters of both fiscal 2012 and fiscal 2011, and 76% and 77% for the first nine months of fiscal 2012 and 2011, respectively. Sales from our focus families (*C. difficile*, Foodborne and *H. pylori*) comprised 63% and 61% of our Diagnostics segments' revenues during the third quarters of fiscal 2012 and 2011, respectively, and 62% and 57% for the nine month periods ended June 30, 2012 and 2011, respectively.

Revenue for the fiscal 2012 third quarter for both of our Diagnostics segments combined increased 6%, reflecting growth in our foodborne (6%) and *C. difficile* (19%) product families, and flat sales in our *H. pylori* product family compared to the prior year quarter. Respiratory product sales, including influenza respiratory products, decreased 2%. On an organic basis, sales for our European Diagnostics segment were flat compared to the prior year third quarter, with the growth in our *C. difficile* product family being offset by sales declines in our *H. pylori*, foodborne and respiratory products.

For the first nine months of fiscal 2012, revenue for both of our Diagnostics segments combined increased 8% from the comparable fiscal 2011 period. This increase reflects growth across all of our focus product families – 7% growth in our *H. pylori* products, 15% growth in our foodborne products and 24% growth in our *C. difficile* products. Excluding the effects of currency translation, our European Diagnostics segment's sales during the nine months ended June 30, 2012 increased 3% relative to the comparable fiscal 2011 period, reflecting the combined effects of growth in our *C. difficile* and *H. pylori* product families, partially offset by a decline in the sales of our foodborne and respiratory products.

As an enterprise with global operations and markets, our business and financial performance are in part dependent upon global economic conditions, and we could be negatively impacted by a global, regional or national economic crisis, including sovereign risk in the event of deterioration in the credit worthiness of, or a default by, local governments. We are particularly susceptible to the economic conditions in countries where government-sponsored healthcare systems are the primary payers for healthcare, including those countries within the European Union that are reducing their public expenditures in an effort to achieve cost savings. While to-date such factors have not had a significant negative impact on our results or operations, we continue to monitor and plan for the potential impact of these global economic factors.

In addition, there have been a number of media reports questioning the longevity of the Euro currency, and whether certain countries might exit the Euro currency. We express no opinion on either of these matters. In the event that the Euro currency would completely dissolve, or in the event certain countries exited the Euro currency, the carrying value of our assets and liabilities in European countries where we have a direct presence could be materially affected as legacy currencies are re-implemented. We continue to monitor this situation and have begun to prepare contingency plans.

### *C. difficile* Products

Our *illumigene*<sup>®</sup> molecular *C. difficile* product has now been available in markets around the world for over 24 months. Sales of this product were approximately \$6,200 and \$16,300 in the three and nine months ended June 30, 2012, respectively. We have approximately 900 customers providing service to in excess of 1,000 hospitals and laboratories worldwide. It generally takes a customer 60-90 days from purchase order placement to become revenue producing – a timeframe we are continually working to reduce. Our *illumigene*<sup>®</sup> molecular *C. difficile* product has restored the *C. difficile* product family to positive sales growth, 19% and 24% during the three and nine months ended June 30, 2012, respectively, and has allowed us to continue to recover lost toxin test volume.

Our major competitors in this product family are Cepheid and Becton Dickinson (molecular) and Alere (immunoassay). We believe that we have several principal advantages versus our competition. First, our molecular instrumentation package has a smaller footprint and significantly lower cost than either Cepheid or Becton Dickinson. We believe that this advantage allows our product to fit into virtually any size hospital or reference laboratory. We believe that our second principal advantage is the breadth of our *C. difficile* product offerings. With the launch of our molecular product and FDA clearance of our common antigen *C. difficile* products – Premier *C. difficile* GDH received FDA clearance in May 2011, and ImmunoCard *C. difficile* GDH received FDA clearance in December 2011 – unlike our primary competitors, we are in a position to offer a full line of testing solutions to our clinical laboratory customers around the world to counter the competitive pressures surrounding this market. Additionally, we hold the only FDA-approved claim for *C. difficile* testing in the pediatric population. These advantages, along with the performance features of the products in our *C. difficile* portfolio, give us a compelling product offering for any hospital testing method preference.

---

## **Table of Contents**

During December 2011, we received FDA clearance for our second molecular test for the *illumigene*<sup>®</sup> molecular platform, *illumigene*<sup>®</sup> Group B *Streptococcus* (GBS). Our GBS test has been placed with over 100 customers, most of which are current *C. difficile* customers. During the quarter, we generated approximately \$300 in GBS revenues; approximately \$600 during the fiscal year-to-date nine month period. Regarding additional tests being developed for the platform: the test for Group A *Streptococcus* has cleared clinical trials and was submitted to the FDA for marketing clearance in July 2012; and the test for *Mycoplasma pneumoniae* is currently in clinical trials and is expected to be submitted to the FDA for marketing clearance later this year. Following these, we expect an *illumigene*<sup>®</sup> platform-based test for *Bordetella pertussis* to clear formal clinical trials and be submitted to the FDA for marketing clearance.

In addition to Cepheid, Becton Dickinson and Alere, other competitors are beginning to enter the *C. difficile* market. Quest Diagnostics and Great Basin recently received FDA clearance for a molecular *C. difficile* test and Quidel received CE marking approval for a molecular *C. difficile* test for sale within the European Union. Although we believe that the breadth of our *C. difficile* product offerings and our low cost molecular platform provide key advantages to the offerings of our competitors, selling prices may come under pressure as more competitors enter the market.

### ***Foodborne Products***

Although our foodborne products are marketed and sold on a global basis, most of our sales volume is within the U.S. Diagnostics segment. We continue to see demand increases in the United States, as laboratories realize the benefits of increased sensitivity and faster turnaround time with our tests for Enterohemorrhagic *E. coli* (EHEC) and *Campylobacter*, compared to traditional culture methods. Sales increases for these products within the U.S. Diagnostics segment were 9% and 17% for the three and nine month periods ended June 30, 2012, respectively.

### ***H. pylori Products***

During the third quarter of fiscal 2012, sales of our *H. pylori* products grew 6% for our U.S. Diagnostics segment; 12% during the nine month fiscal year-to-date period. This increase in our U.S. Diagnostics segment continues to reflect the benefits of our partnerships with managed care companies in promoting the health and economic benefits of a test and treat strategy, and the ongoing effects of such strategy moving physician behavior away from serology-based testing toward direct antigen testing. Compared to the third quarter of fiscal 2011, sales of *H. pylori* products for our European Diagnostics segment declined 3% on an organic basis for the third quarter of fiscal 2012, due in large part to order patterns of certain distributors. Such sales grew 3% for the year-over-year nine month periods ended June 30.

### ***Group Purchasing Organizations and Integrated Delivery Networks***

In our U.S. Diagnostics segment, consolidation of the U.S. healthcare industry over the last several years has led to the creation of group purchasing organizations (GPOs) and integrated delivery networks (IDNs) that aggregate buying power for hospital groups and put pressure on our selling prices. We have multi-year supply agreements with several GPOs and IDNs. These agreements help secure our products with these customers and lead to new business.

### ***Life Science Segment***

Sales for our Life Science segment increased 4% for the third quarter of fiscal 2012 and 15% for the nine month fiscal year-to-date period, reflecting increases in both our core bulk reagent business (1% quarterly and 16% year-to-date) and our molecular reagent business (9% quarterly and 13% year-to-date). The year-to-date increase in the core bulk reagent business largely results from the completion of certain contract manufacturing projects and increased orders for Rubella and Hepatitis A proteins. Our molecular reagent business, operated through our Bioline Group, continues to benefit from its new product launches and advancements during recent months – most notably its new SensiFAST and MyTaq PCR components. Revenues for our Life Science segment are inherently dependent upon customer order patterns and timing of contract manufacturing work. We expect revenues for the fourth quarter of fiscal 2012 to be in the range of \$9,000 to \$10,000.

## **Table of Contents**

### ***Foreign Currency***

During the third quarter of fiscal 2012, currency exchange rates had an approximate \$800 unfavorable impact on revenue; \$650 within the European Diagnostics segment and \$150 in the Life Science segment. This compares to currency exchange having an approximate \$650 favorable impact on revenue in the third quarter of fiscal 2011. On a nine month year-to-date basis, currency exchange rates had an approximate \$1,040 unfavorable impact on fiscal 2012 revenue; \$890 within the European Diagnostics segment and \$150 in the Life Science segment. This compares to currency exchange having an approximate \$165 favorable impact on revenue in the first nine months of fiscal 2011.

The volatility in the Euro-USD exchange rate increased significantly during the quarter, and this may continue into the foreseeable future until such time as the sovereign debt crisis situation in Europe is resolved. Each one-point decline in the Euro-USD exchange rate (e.g., 1.28 to 1.27) negatively affects the revenues of our European Diagnostics segment by approximately \$170. However, we would not expect such exchange rate fluctuations to have a significant impact on operating income. This results from the fact that we are also exposed to foreign currency risk related to the supply of certain European-manufactured diagnostic test kits, which serves to provide a natural hedge against the impact on European Diagnostics revenue.

### ***Significant Customers***

Two national distributors in our U.S. Diagnostics segment accounted for 48% and 47% of total sales for this segment for the third quarters of fiscal 2012 and 2011, respectively, and 49% and 50% during the nine months ended June 30, 2012 and 2011, respectively.

Two diagnostic manufacturing customers in our Life Science segment accounted for 11% and 15% of total sales for this segment for the third quarters of fiscal 2012 and 2011, respectively, and 20% and 14% during the nine months ended June 30, 2012 and 2011, respectively. The fluctuation in the percentage of sales in both periods reflects the inherent volatility in the buying patterns of these customers.

### **Segment Revenues**

Our reportable segments are U.S. Diagnostics, European Diagnostics and Life Science. Initial segmentation between Diagnostics and Life Science has been determined based upon products and customers, with further segmentation of Diagnostics between U.S. and European being based upon geographic regions served and management responsibility. The U.S. Diagnostics segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the U.S. and countries outside of Australia, Europe, Africa and the Middle East. The European Diagnostics segment consists of the sale and distribution of diagnostic test kits in Australia, Europe, Africa and the Middle East. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad. The Life Science segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Revenues for the Diagnostics segments, in the normal course of business, may be affected from quarter to quarter by buying patterns of major distributors, seasonality and strength of certain diseases, and foreign currency exchange rates. Revenues for the Life Science segment, in the normal course of business, may be affected from quarter to quarter by the timing and nature of arrangements for contract services work, which may have longer production cycles than bioresearch reagents and bulk antigens and antibodies, as well as buying patterns of major customers, and foreign currency exchange rates. We believe that the overall breadth of our product lines serves to reduce the variability in consolidated revenues.

**Table of Contents**

Revenues for each of our segments are shown below.

	Three Months Ended June 30,			Nine Months Ended June 30,		
	2012	2011	Inc (Dec)	2012	2011	Inc (Dec)
U.S. Diagnostics	\$ 26,234	\$ 23,829	10%	\$ 80,091	\$ 72,007	11%
European Diagnostics	5,897	6,612	(11)%	18,326	18,926	(3)%
Life Science	10,010	9,611	4%	31,431	27,441	15%
Consolidated	\$ 42,141	\$ 40,052	5%	\$ 129,848	\$ 118,374	10%
International -						
U.S. Diagnostics	\$ 1,420	\$ 1,845	(23)%	\$ 4,637	\$ 5,058	(8)%
European Diagnostics	5,897	6,612	(11)%	18,326	18,926	(3)%
Life Science	5,737	5,365	7%	18,535	15,238	22%
Total	\$ 13,054	\$ 13,822	(6)%	\$ 41,498	\$ 39,222	6%
% of total sales	31%	35%		32%	33%	

**Gross Profit**

	Three Months Ended June 30,			Nine Months Ended June 30,		
	2012	2011	Change	2012	2011	Change
Gross Profit	\$ 27,643	\$ 25,351	9%	\$ 82,126	\$ 74,810	10%
Gross Profit Margin	66%	63%	+3 points	63%	63%	None

The overall gross profit margin increase for the third quarter of fiscal 2012 results primarily from the combined effects of the mix of products sold, as well as the mix of sales from the Company's segments.

Our overall operations consist of the sale of diagnostic test kits for various disease states and in alternative test formats, as well as bio research reagents, bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, proficiency panels, contract research and development, and contract manufacturing services. Product sales mix shifts, in the normal course of business, can cause the consolidated gross profit margin to fluctuate by several points.

**Table of Contents****Operating Expenses**

	Three Months Ended June 30, 2012				
	Research & Development	Selling & Marketing	General & Administrative	Other (1)	Total Operating Expenses
<b>2011 Expenses</b>	\$ 2,693	\$ 5,968	\$ 6,559	\$	\$ 15,220
% of Sales	7%	15%	16%	%	38%
Fiscal 2012 Increases (Decreases):					
U.S. Diagnostics	(30)	(274)	(124)		(428)
European Diagnostics		(89)	182		93
Life Science	(3)	238	(455)	366	146
<b>2012 Expenses</b>	\$ 2,660	\$ 5,843	\$ 6,162	\$ 366	\$ 15,031
% of Sales	6%	14%	15%	1%	36%
% Increase (Decrease)	(1)%	(2)%	(6)%	NMF	(1)%

	Nine Months Ended June 30, 2012				
	Research & Development	Selling & Marketing	General & Administrative	Other (1)	Total Operating Expenses
<b>2011 Expenses</b>	\$ 7,328	\$ 17,041	\$ 19,018	\$ 1,240	\$ 44,627
% of Sales	6%	14%	16%	1%	38%
Fiscal 2012 Increases (Decreases):					
U.S. Diagnostics	361	(676)	884	(365)	204
European Diagnostics		22	366	(875)	(487)
Life Science	(248)	805	(1,032)	1,013	538
<b>2012 Expenses</b>	\$ 7,441	\$ 17,192	\$ 19,236	\$ 1,013	\$ 44,882
% of Sales	6%	13%	15%	1%	35%
% Increase (Decrease)	2%	1%	1%	(18)%	1%

(1) Comprised of costs related to reorganizing our sales and marketing leadership (2011) and consolidating our Maine and Tennessee operations (2012).

Overall, the relative stability in total operating expense during both the third quarter and first nine months of fiscal 2012 continues to result in large part from the combined effects of our (i) ongoing efforts to control spending in each of our segments while investing the necessary resources in our strategic areas of growth; (ii) beginning to realize cost savings from the consolidation of our Core Life Science operations into one facility; (iii) incurring costs in connection with the consolidation of our Saco, Maine operations into our Memphis, Tennessee location during the three and nine months ended June 30, 2012 of approximately \$366 and \$1,013, respectively; and (iv) incurring during the second quarter of fiscal 2011 approximately \$1,240 of costs in connection with the reorganization of our European and Global Sales and Marketing Leadership. The Maine and Tennessee facility consolidation costs incurred during the third quarter of fiscal 2012 and year-to-date period relate primarily to retention bonus costs for personnel scheduled to terminate at varying times during fiscal 2012 and an additional write-down of the Maine building facility.



---

## **Table of Contents**

### **Operating Income**

Operating income increased 24% to \$12,612 for the third quarter of fiscal 2012, and increased 23% to \$37,244 for the first nine months of fiscal 2012, as a result of the factors discussed above.

### **Other Income and Expense**

The decrease in other income, net, during the nine month year-to-date period can primarily be attributed to the net effects of an improvement in net currency exchange gains/losses of approximately \$100 and a decrease in grant income from a foreign governmental agency of approximately \$170.

### **Income Taxes**

The effective rate for income taxes was 32% for the third quarter and 34% for the first nine months of fiscal 2012, which on a quarterly basis is one percentage point lower than the corresponding prior year period and flat on a year-to-date basis. The decrease in rates primarily results from the effect of adjusting, upon filing of the federal tax return, the previously estimated permanent and temporary differences between income for financial reporting purposes and income for tax purposes. For the fiscal year ending September 30, 2012, we expect the effective tax rate to approximate 35%.

### **Liquidity and Capital Resources**

#### ***Comparative Cash Flow Analysis***

Our cash flow and financing requirements are determined by analyses of operating and capital spending budgets, consideration of acquisition plans, and consideration of common share dividends. We have historically maintained a credit facility to augment working capital requirements and to respond quickly to acquisition opportunities. Our investment portfolio presently contains overnight repurchase agreements.

We have an investment policy that guides the holdings of our investment portfolio. Our objectives in managing the investment portfolio are to (i) preserve capital; (ii) provide sufficient liquidity to meet working capital requirements and fund strategic objectives such as acquisitions; and (iii) capture a market rate of return commensurate with market conditions and our policy's investment eligibility criteria. As we look forward, we will continue to manage the holdings of our investment portfolio with preservation of capital being the primary objective.

At the present time, we do not expect current conditions in the financial markets, or overall economic conditions to have a significant impact on our liquidity needs, financial condition, or results of operations, although no assurances can be made in this regard. We intend to continue to fund our working capital requirements and dividends from current cash flows from operating activities and cash on hand. If needed, we also have an additional source of liquidity through our \$30,000 bank credit facility, which we expect to renew prior to its expiration on September 15, 2012. Approximately \$5,300 of our accounts receivable at June 30, 2012 is due from Italian hospital customers whose funding ultimately comes from the Italian government. During the fourth quarter of fiscal 2011 and first quarter of fiscal 2012, we experienced a deterioration in the aging of our Italian accounts receivable. While such aging appeared to stabilize during the second and third quarters of fiscal 2012, we continue to monitor such accounts closely. Our liquidity needs may change if overall economic conditions worsen and/or liquidity and credit within the financial markets remains tight for an extended period of time, and such conditions impact the collectibility of our customer accounts receivable or credit terms with our vendors, or disrupt the supply of raw materials and services.

Net cash provided by operating activities increased 92% for the first nine months of fiscal 2012 to \$31,888, reflecting the 23% increase in net earnings and the effects of net working capital changes related to our investments in *illumigene*<sup>®</sup> inventory and the timing of payments with suppliers. Net cash flows from operating activities and cash on hand are anticipated to be adequate to fund working capital requirements, capital expenditures and dividends during the next 12 months. During the third quarter of fiscal 2012, our \$0.19 per share cash dividend approximated 90% of our quarterly diluted earnings per share, nearly in line with the Company's long-standing policy of setting a payout ratio of between 75% and 85% of each fiscal year's expected net earnings. We believe that this positive dividend payout relationship will continue, although no assurances can be made in this regard. During the first nine months of fiscal 2012, cash generated from the Company's operating activities exceeded the quarterly dividend by 36%.

---

**Table of Contents**

***Capital Resources***

We have a \$30,000 credit facility with a commercial bank that expires on September 15, 2012, which we expect to renew. As of July 31, 2012, there were no borrowings outstanding on this facility and we had 100% borrowing capacity available to us. We have had no borrowings outstanding under this facility during the first nine months of fiscal 2012, or during the full year of fiscal 2011.

Our capital expenditures are estimated to range between approximately \$3,000 to \$5,000 for fiscal 2012, with the actual amount depending upon actual operating results and the phasing of certain projects. Such expenditures may be funded with cash and equivalents on hand, operating cash flows, and/or availability under the \$30,000 credit facility discussed above.

We do not utilize any special-purpose financing vehicles or have any undisclosed off-balance sheet arrangements.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

There have been no material changes in the Company's exposure to market risk since September 30, 2011.

**ITEM 4. CONTROLS AND PROCEDURES**

As of June 30, 2012, an evaluation was completed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) and 15d-15(b) promulgated under the Securities Exchange Act of 1934, as amended. Based on that evaluation, our management, including the CEO and CFO, concluded that our disclosure controls and procedures were effective as of June 30, 2012. There have been no changes in our internal control over financial reporting identified in connection with the evaluation of internal control that occurred during the third quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, or in other factors that could materially affect internal control subsequent to June 30, 2012.

**PART II. OTHER INFORMATION**

**ITEM 1A. RISK FACTORS**

There have been no material changes from risk factors as previously disclosed in the Registrant's Form 10-K in response to Item 1A to Part I of Form 10-K.

**ITEM 6. EXHIBITS**

The following exhibits are being filed or furnished as a part of this Quarterly Report on Form 10-Q.

- 31.1 Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)
- 31.2 Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a)
- 32 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 101 The following financial information from Meridian Bioscience Inc.'s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 filed with the SEC on August 9, 2012, formatted in XBRL includes: (i) Condensed Consolidated Statements of Operations for the three and nine months ended June 30, 2012 and 2011, (ii) Condensed Consolidated Statements of Cash Flows for the nine months ended June 30, 2012 and 2011, (iii) Condensed Consolidated Balance Sheets as of June 30, 2012 and September 30, 2011, (iv) Condensed Consolidated Statement of Shareholders' Equity for the nine months ended June 30, 2012, and (v) the Notes to Condensed Consolidated Financial Statements

**Table of Contents**

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 9, 2012

**MERIDIAN BIOSCIENCE, INC.**

/s/ Melissa A. Lueke  
Melissa A. Lueke  
Executive Vice President and Chief

Financial Officer

Page 20